Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Alternative capsid strategies for targeting recombinant AAV gene therapy

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

Cover image Placeholder

The advent of new serotypes of adeno-associated viruses (AAV) has expanded the tissue tropism and allowed clinically relevant numbers of cells to be transduced by rAAV vectors. The two most significant obstacles in the way of future gene therapies with AAV vectors are tissue/target cell specificity and sitel-specific integration. Other reviews contained in this issue will look at advances in site-specific integration. This review will focus on the latest developments in AAV vector tropism and tissue/ target cell specificity.


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation